Understanding ICD-10 Coding For Metastatic Adenocarcinoma Of The Lung

What is Metastatic Adenocarcinoma of Lung?

Metastatic adenocarcinoma of the lung is a type of cancer that originates in the lung and spreads to other parts of the body. Adenocarcinoma is a type of non-small cell lung cancer that starts in the cells that line the alveoli (tiny air sacs) of the lungs. When these cancer cells spread to other organs or tissues in the body, it is known as metastatic adenocarcinoma.

Code Information

The ICD-10 code for metastatic adenocarcinoma of the lung is C34.90. This code is used to classify and code diagnoses and procedures associated with this type of cancer.

Diagnostic Related Groups (MS-DRG)

ICD--CM Diagnosis Code C
ICD–CM Diagnosis Code C

Metastatic adenocarcinoma of the lung falls under MS-DRG 166 – Other Respiratory System Diagnoses with MCC (Major Complications or Comorbidities). This DRG categorizes patients with lung cancer who have significant complications or comorbidities that impact their treatment and outcomes.

Convert to ICD-9 Code

In ICD-9, metastatic adenocarcinoma of the lung is coded as 162.9. This code is used to indicate primary malignant neoplasm of the trachea, bronchus, and lung when the cancer has spread to other parts of the body.

Code History

American Thoracic Society - ICD--CM Coding for Interstitial Lung
American Thoracic Society – ICD–CM Coding for Interstitial Lung

The ICD-10 code for metastatic adenocarcinoma of the lung was introduced in 2015 as part of the implementation of the tenth revision of the International Classification of Diseases.

Approximate Synonyms

Other terms used to describe metastatic adenocarcinoma of the lung include secondary lung cancer, metastatic lung tumor, and advanced lung carcinoma.

Clinical Information

Metastatic Lung Cancer and ICD-: A New Perspective on Diagnosis
Metastatic Lung Cancer and ICD-: A New Perspective on Diagnosis

Metastatic adenocarcinoma of the lung is a serious and aggressive form of cancer that requires prompt diagnosis and treatment. Symptoms of metastatic lung cancer can vary depending on where the cancer has spread, but common symptoms include persistent cough, chest pain, shortness of breath, and unexplained weight loss.

Causes

The exact cause of metastatic adenocarcinoma of the lung is not fully understood, but it is believed to be linked to genetic mutations and exposure to risk factors such as smoking, secondhand smoke, radon gas, and environmental pollutants.

Symptoms

Lung Cancer: ICD--CM Coding - AAPC Knowledge Center
Lung Cancer: ICD–CM Coding – AAPC Knowledge Center

Common symptoms of metastatic adenocarcinoma of the lung include:

Persistent cough
Chest pain
Shortness of breath
Unexplained weight loss
Coughing up blood
Fatigue
Hoarseness
Wheezing
Recurrent respiratory infections

It is important to note that these symptoms can be caused by other conditions, so it is essential to consult a healthcare professional for an accurate diagnosis.

Diagnosis

Diagnosing metastatic adenocarcinoma of the lung usually involves a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, as well as biopsies to confirm the presence of cancer cells in the lung tissue.

Treatment

Treatment for metastatic adenocarcinoma of the lung may include surgery to remove the tumor, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The choice of treatment depends on the stage of the cancer, the patient’s overall health, and other factors.

Conclusion

Metastatic adenocarcinoma of the lung is a serious and aggressive form of cancer that requires prompt diagnosis and treatment. Early detection and a personalized treatment plan can improve outcomes and quality of life for patients with this condition.

FAQs

1. What are the risk factors for metastatic adenocarcinoma of the lung?

Risk factors for lung cancer include smoking, exposure to secondhand smoke, radon gas, and environmental pollutants.

2. How is metastatic adenocarcinoma of the lung treated?

Treatment may include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

3. What are the

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button